Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion

Trastuzumab beyond progression in HER2-positive advanced breast cancer: The Royal Marsden experience

(2011) T Waddell et al.   BRITISH JOURNAL OF CANCER

Depleting regulatory T cells with arginine-rich, cell-penetrating, peptide-conjugated morpholino oligomer targeting FOXP3 inhibits regulatory T-cell function

(2011) M A Morse et al.   CANCER GENE THERAPY

An Adenoviral Vaccine Encoding Full-Length Inactivated Human Her2 Exhibits Potent Immunogenicty and Enhanced Therapeutic Efficacy without Oncogenicity

(2010) Z. C. Hartman et al.   CLINICAL CANCER RESEARCH

Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells

(2010) Norma O’Donovan et al.   INVESTIGATIONAL NEW DRUGS

Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer

(2010) Kimberly L. Blackwell et al.   JOURNAL OF CLINICAL ONCOLOGY

Improved Endpoints for Cancer Immunotherapy Trials

(2010) A. Hoos et al.   JNCI-Journal of the National Cancer Institute

Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens

(2009) K. L. Blackwell et al.   ANNALS OF ONCOLOGY

Regulatory T-Cell-Mediated Attenuation of T-Cell Responses to the NY-ESO-1 ISCOMATRIX Vaccine in Patients with Advanced Malignant Melanoma

(2009) T. Nicholaou et al.   CLINICAL CANCER RESEARCH

Concurrent Trastuzumab and HER2/neu-Specific Vaccination in Patients With Metastatic Breast Cancer

(2009) Mary L. Disis et al.   JOURNAL OF CLINICAL ONCOLOGY

Antibody responses against NY-ESO-1 and HER2 antigens in patients vaccinated with combinations of cholesteryl pullulan (CHP)-NY-ESO-1 and CHP-HER2 with OK-432

(2009) Masatoshi Aoki et al.   VACCINE

Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses

(2008) M. M. Hipp et al.   BLOOD

Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines

(2008) M. A. Morse et al.   BLOOD

Humoral immune responses in patients vaccinated with 1–146 HER2 protein complexed with cholesteryl pullulan nanogel

(2008) Shinichi Kageyama et al.   CANCER SCIENCE

Stem Cell–Related “Self-Renewal” Signature and High Epidermal Growth Factor Receptor Expression Associated With Resistance to Concomitant Chemoradiotherapy in Glioblastoma

(2008) Anastasia Murat et al.   JOURNAL OF CLINICAL ONCOLOGY

Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation

(2008) W Zhao et al.   LEUKEMIA

Lapatinib Resistance in HCT116 Cells Is Mediated by Elevated MCL-1 Expression and Decreased BAK Activation and Not by ERBB Receptor Kinase Mutation

(2008) A. P. Martin et al.   MOLECULAR PHARMACOLOGY